|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Advanced gastric cancer:Is there enough evidence to call second-line therapy standard?显示文摘Gastric cancer and cancer of the gastro-oesophageal junction(GOJ) are the 4th most common cancer diagnoses worldwide with regional differences in incidence rates.The treatment of gastric and GOJ cancers is complex and requires multimodality treatment including chemotherapy treatment,surgery,and radiotherapy.During the past decade considerable improvements were achieved by advanced surgical techniques,tailored chemotherapies/radiotherapy and technical innovations in clinical diagnostics.In patients with advanced or metastatic gastric/GOJ cancer systemic chemotherapy with fluoropyrimidine/platinum-based regimens(+/-human epidermal growth factor receptor-2 antibody) is the mainstay of treatment.Despite these improvements,the clinical outcome for patients with advanced or metastatic disease is generally poor with 5-year survival rates ranging between 5%-15%.These poor survival rates may to some extent be related that standard therapies beyond first-line therapies have never been defined.Considering that this patient population is often not fit enough to receive further treatments there is an increasing body of evidence from phase-2 studies that in fact second-line therapies may have a positive impact in terms of overall survival.Moreover two recently published phase-3 studies support the use of second-line chemotherapy.A South Korean study compared either,irinotecan or docetaxel with best supportive care and a German study compared irinotecan with best supportive care-both studies met their primary endpoint overall survival.In this 'Field of Vision' article,we review these recently published phase-3 studies and put them into the context of clinical prognostic factors helping to guide treatment decisions in patients who most likely benefit. | Hendrik-Tobias Arkenau Matilde Saggese Charlotte Lemech | 2012 | World Journal of Gastroenterology2012，18，44： | 12 |
| 2 | Diagnosing prodromal Alzheimer’s disease: Role of CSF biochemical markers显示文摘 | Lucilla Parnetti Alessia Lanari Giorgio Silvestrelli Emanuele Saggese Paolo Reboldi | 2005 | Mechanisms of Ageing and Development2005，，2： | 2 |
| 3 | Sex steroids and the acquisition of bone mass 显示文摘 | Saggese G Bertel|oni S Baroncelli GI | 1997 | Hoom Res1997，48，5： | 1 |
| 4 | Expression of osteoprotegerin(OPC),TNF related apoptosis inducing ligand(TRAIL),and receptor activator of nuclear factor kappaB ligand(RANKL)in human breast tumours显示文摘 | Van Poznak C Cross SS Saggese M | 2006 | J Clin Pathol2006，59，1： | 1 |
| 5 | Hypomagnesemia and the parathyroid hormone-vitamin D endocrine system in children with insulin-dependent diabetes mel itus:effect of magnesium administration显示文摘 | Saggese G Federico G Bertel oni S | | 0，，： | 1 |
| 6 | Growth velocity and serum aminoterminal propeptide of type III procollagen in precocious puberty during gonadotropin releasing hormone analogue treatment显示文摘 | Saggese G Bertelloni S Baroncelli GI | 1993 | Acta Paediatr1993，82，： | 1 |
| 7 | Effect of com- bined treatment with gonadotropin releasing hormone ana- logue and growth hormone in patients with central preco- cious puberty who had subnormal growth velocity and im- paired height prognosis 显示文摘 | Saggese G Pasquino AM Bertelloni S | 1995 | Acta Paediatr1995，84，： | 1 |
| 8 | An experimental study of soft error in microprocessors显示文摘 | G P Saggese | 2005 | IEEE Micro2005，25，6： | 1 |
| 9 | Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits 显示文摘 | Calabresi P Galletti F Saggese E | 2007 | ParkinsonismRelat Disord2007，13，3： | 1 |
| 10 | Cervical ectopic thymus: a case report and review of the literature显示文摘 | Ceroni Compadretti G Cartaroni C | 2002 | Int J Pediatr Otorhinolaryngol2002，2166，1： | 1 |
| 11 | Reduction of bone density: An effect of gonadotropin-releasing hormone analogue treatment in central precocious puberty显示文摘 | Saggese G Beretlloni S Baroncelli GI | 1993 | Eur J Pediatr1993，152，9： | 1 |
| 12 | Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours 显示文摘 | Van Poznak C Cross SS Saggese M | 2006 | J Clin Pathol2006，59，： | 1 |
| 13 | Use o{ combined Gn- RH agonist and hGH therapy for better attaining the goals in precocious puberty treatment 显示文摘 | Tat6 L Saggese G Cavallo L | 1995 | Horm Res1995，44，3： | 1 |
| 14 | Neuronal networks and synaptic plasticity in Parkinson's disease:beyond motor deficits 显示文摘 | Calabresi P Galletti F Saggese E | 2007 | Parkinsonism Relat Disord2007，13，3： | 1 |
| 15 | Ectopic TSH-secreting pituitary adenoma of the vomerosphenoidal junction显示文摘 | Pasquini E Faustini-Fustini M Sciarretta V Saggese D Roncaroli F Serra D Frank G | 2003 | Eur J Endocrinol2003，148，2： | 1 |
| 16 | Use of solid-phase microextraction coupled to gas chromatography-mass spectrometry for determination of urinary volatile organic compounds in autistic children compared with healthy controls显示文摘 | Cozzolino R De Magistris L Saggese P | 2014 | Anal Bioanal Chem2014，406，19： | 1 |
| 17 | Effect of comblined treatment with gonadotropin relasing hormone analogue and growth hormone inpatients with central precocious puberty who had sub- normal growth velocity and impaired height velocity显示文摘 | Saggese G Pasquine A Bertelloni S | 1995 | Acat Pediatr1995，84，2： | 1 |
| 18 | Oestrogenic mycotoxin exposures andprecociouspubertal development 显示文摘 | Massart F Saggese G | 2010 | Int J Androl2010，33，2： | 1 |
| 19 | The effect of admin-istering gonadotropin-releasing hormone agonist with recom-binant-human growth hormone (GH) on the final height ofgirls with isolated GH deficiency: results from a controlledstudy显示文摘 | Saggese G Federico G Barsanti S | 2001 | J Clin Endocrinol Metab2001，86，5： | 1 |
| 20 | Analysis ofInclusions in Submerged Arc Welds in Microalloyed Steels显示文摘 | Bhatti A R Saggese M E Hawkins D N | 1984 | Weld1984，63，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员